Tinggalkan pesan
Kami akan segera menghubungi Anda kembali!
Pesan Anda harus antara 20-3.000 karakter!
Silakan periksa email Anda!
Lebih banyak informasi memfasilitasi komunikasi yang lebih baik.
Berhasil dikirim!
Kami akan segera menghubungi Anda kembali!
Tinggalkan pesan
Kami akan segera menghubungi Anda kembali!
Pesan Anda harus antara 20-3.000 karakter!
Silakan periksa email Anda!
—— PHARMA SIMPOR
—— Nasir
—— IATEC, Argentina
—— Mohammed Saad
Veterinary drug development requires the same strict sterility and contamination control standards as human pharmaceutical manufacturing, and modular cleanrooms have emerged as a flexible, cost-effective solution tailored to the unique needs of veterinary research and production. Unlike permanent cleanroom facilities, modular units can adapt to the varying scale and timeline of veterinary drug projects, from early-stage preclinical testing to small-batch production of specialized biologics.
Modular cleanrooms for veterinary applications are engineered to meet ISO 14644-1 classification requirements aligned with product risk: sterile injectable animal vaccines and biologics demand ISO Class 5 or 7 controlled environments, while oral compounding and non-sterile formulation development operate effectively in lower-class modular zones. Pre-integrated HEPA filtration, positive pressure zoning and smooth, easy-to-decontaminate panel surfaces prevent cross-contamination between different drug candidates and limit microbial load that could compromise trial integrity.
The scalability of modular design addresses the specific dynamics of veterinary drug development. Many veterinary projects target niche species or smaller market sizes, so teams do not need to invest in oversized permanent facilities. Modular cleanrooms can be expanded as pipeline candidates advance, or relocated between research sites, and reconfigured to accommodate new biosafety protocols for zoonotic pathogen research. This flexibility reduces upfront capital expenditure by 30–50% compared to traditional construction, making controlled production accessible to smaller veterinary biotech firms

